Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.

Regeneron remains committed to supporting patient access to medications and believes that patients should be able to access whatever therapy their physician prescribes for them.

On June 17, 2025, Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed another complaint against Amgen Inc. (“Amgen”) under the BPCIA, alleging that ...

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

Regeneron launches a $200 million matching donation program for Good Days’ Retinal Disease Fund to enhance patient access to medicines.

Regeneron will announce Q2 2025 results on August 1, 2025, and host a conference call at 8:30 AM ET. Regeneron Pharmaceuticals, Inc. announced that it will disclose its second quarter 2025 ...

Florida State lands Chaminade Madonna's football and hoop star Jasen Lopez. He will play both spots for the Seminoles.

TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on ...

Photo: Congratulations to the Regeneron Science Talent Search top three finalists (from left to right) Achyuta Rajaram, with second place winner Thomas Cong and third place awardee Michelle Wei.

Review the current valuation for Regeneron Pharmaceuticals Inc (REGN:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Regeneron has asserted the ’865 patent in BPCIA litigations against Mylan, Samsung Bioepis, Celltrion, Formycon, and Amgen.

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a higher bid.